Dr. Joshi Advocates Comprehensive GLP-1 Treatment Protocols in India
Dr. Shashank Joshi emphasizes the need for tailored GLP-1 therapy protocols in India, focusing on overall health rather than just weight loss.
GLP-1 therapies should integrate nutritional assessments and lifestyle changes.
The unique 'thin-fat' Indian phenotype necessitates a different treatment approach.
Success in treatment should focus on metabolic health and functional outcomes, not just weight loss.
In a recent discussion, Dr. Shashank R. Joshi from Lilavati Hospital highlighted the necessity for personalized treatment protocols for GLP-1 therapies in India. He argues that while these medications are effective for managing diabetes and obesity, their use must extend beyond mere weight loss to encompass a holistic approach that includes nutritional assessments and lifestyle modifications. This perspective is particularly crucial given the alarming statistics from the ICMR-INDIAB study, which reveal that 101 million Indians are living with diabetes and 136 million with pre-diabetes.
Dr. Joshi pointed out that the traditional view of GLP-1 drugs as simple weight-loss solutions is misleading. Instead, he categorizes them as potent anti-diabetic therapies that can significantly reduce complications related to diabetes, including cardiovascular and kidney diseases. He stresses that these medications should be prescribed under medical supervision and integrated with lifestyle interventions from the outset, emphasizing the importance of nutrition, hydration, and strength training in the treatment regimen.
A significant aspect of Dr. Joshi's argument is the unique body composition of Indian patients, often referred to as the 'thin-fat Indian phenotype.' This condition, characterized by individuals appearing lean yet having high body fat and low muscle mass, complicates diabetes management. Dr. Joshi notes that Indians typically develop metabolic complications at younger ages and lower BMI levels compared to Western populations, necessitating a tailored approach that considers regional dietary habits and nutritional needs.
Furthermore, Dr. Joshi advocates for a comprehensive assessment of patients before initiating treatment. This includes evaluating bone mineral density, muscle mass, and hydration levels, as well as monitoring functional abilities like grip strength. He warns that appetite suppression caused by GLP-1 therapies could lead to nutritional deficiencies if not properly managed. Therefore, he insists that nutritional quality must be prioritized, especially when calorie intake is significantly reduced.
Looking ahead, Dr. Joshi envisions a shift in India's healthcare framework towards a multidisciplinary approach that integrates endocrinologists, nutritionists, and other healthcare providers. This collaborative model aims to ensure that patients receive comprehensive care, including counseling and structured lifestyle protocols. He concludes that the ultimate measure of success in GLP-1 therapy should be the improvement in metabolic and functional health, rather than the amount of weight lost.



